Aneela Nomura

Dr. Aneela Nomura

RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MYMotoi Yamashita
Motoi Yamashita
COChihiro Ogawa
Chihiro Ogawa
BZBaihao Zhang
Baihao Zhang
TKTetsuro Kobayashi
Tetsuro Kobayashi
ANAneela Nomura
Aneela Nomura
ITIchiro Taniuchi
Ichiro Taniuchi
Despite its broad application in in vitro studies, the application of targeted protein degradation (TPD) to animal models faces considerable challenges. Here, we develop inducible and cell-type specific TPD systems in mice using two degron systems: Oryza sativa TIR1F74G (OsTIR1)-auxin-inducible degron 2 (AID2) and human cereblon (hCRBN)-SALL4 degron (S4D). Efficient degradation of Satb1Venus protein by these systems recapitulates phenotypes observed in the Satb1-deficient mice. These TPD are successfully applied in both the fetal and neonatal stages. The OsTIR1-AID2 system proves to be effective for membrane proteins such as PD-1, emulating the effects of the anti-PD-1 antibody. Degradation of Bcl11b reveals a role of Bcl11b which was not characterized by the Cre-loxP system. Collectively, in vivo TPD technologies developed in this study enable inducible, temporal, and cell type-specific depletion of target proteins with high efficacy in mice. These technologies have a wide range of applications in the diverse fields of biological and medical research.

18 June 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
LSLaura Spinelli
Laura Spinelli
JMJulia M. Marchingo
Julia M. Marchingo
ANAneela Nomura
Aneela Nomura
MDMarcos P. Damasio
Marcos P. Damasio
DCDoreen A. Cantrell
Doreen A. Cantrell
Phosphoinositide 3-kinase p110 delta (PI3K p110δ) is pivotal for CD8+ T cell immune responses. The current study explores PI3K p110δ induction and repression of antigen receptor and cytokine regulated programs to inform how PI3K p110δ directs CD8+ T cell fate. The studies force a revision of the concept that PI3K p110δ controls metabolic pathways in T cells and reveal major differences in PI3K p110δ regulated transcriptional programs between naïve and effector cytotoxic T cells (CTL). These differences include differential control of the expression of cytolytic effector molecules and costimulatory receptors. Key insights from the work include that PI3K p110δ signalling pathways repress expression of the critical inhibitory receptors CTLA4 and SLAMF6 in CTL. Moreover, in both naïve and effector T cells the dominant role for PI3K p110δ is to restrain the production of the chemokines that orchestrate communication between adaptive and innate immune cells. The study provides a comprehensive resource for understanding how PI3K p110δ uses multiple processes mediated by Protein Kinase B/AKT, FOXO1 dependent and independent mechanisms and mitogen-activated protein kinases (MAPK) to direct CD8+ T cell fate.

1 November 2020 in Trends in Immunology
Verified
Journal Article
Open access
ANAneela Nomura
Aneela Nomura
ITIchiro Taniuchi
Ichiro Taniuchi
During mammalian T cell development, CD4+CD8+ double-positive (DP) thymocytes must make a lineage choice to become either conventional CD4+ or CD8+ T cells, dependent on their specificity for MHC-II or MHC-I, respectively. Alternatively, DP thymocytes can decide to become innate-like T cells in response to nonclassical MHC-I molecules. A key feature is the downregulation of CD8, which causes transient T cell receptor (TCR) signaling in MHC-I-selected DP thymocytes. Hence, this kinetic signaling model postulates that short or long duration of TCR signals during positive selection can direct the development of cytotoxic or helper T cell lineages. In this opinion article, we discuss the effects of constitutive expression of transgenic CD8 and prolonged TCR signaling on T cell lineage choice in MHC-I selected mouse thymocytes.

16 May 2023 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
ANAneela Nomura
Aneela Nomura
TKTetsuro Kobayashi
Tetsuro Kobayashi
WSWooseok Seo
Wooseok Seo
MOMichiko Ohno-Oishi
Michiko Ohno-Oishi
KKKiyokazu Kakugawa
Kiyokazu Kakugawa
ITIchiro Taniuchi
Ichiro Taniuchi
The genome organizer, special AT-rich binding protein-1 (SATB1), functions to globally regulate gene networks during primary T cell development and plays a pivotal role in lineage specification in CD4+helper-, CD8+cytotoxic-, and FOXP3+regulatory-T cell subsets. However, it remains unclear howSatb1gene expression is controlled, particularly in effector T cell function. Here, by using a novel reporter mouse strain expressing SATB1-Venus and genome editing, we have identified acis-regulatory enhancer, essential for maintainingSatb1expression specifically in TH2 cells. This enhancer is occupied by STAT6 and interacts withSatb1promoters through chromatin looping in TH2 cells. Reduction ofSatb1expression, by the lack of this enhancer, resulted in elevated IL-5 expression in TH2 cells. In addition, we found thatSatb1is induced in activated group 2 innate lymphoid cells (ILC2s) through this enhancer. Collectively, these results provide novel insights into howSatb1expression is regulated in TH2 cells and ILC2s during type 2 immune responses.

3 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
WSWooseok Seo
Wooseok Seo
ANAneela Nomura
Aneela Nomura
ITIchiro Taniuchi
Ichiro Taniuchi
The Runt-related transcription factor (RUNX) family of proteins are crucial for many developmental and immuno-physiological processes. Their importance in cellular and tissue development has been repeatedly demonstrated as they are often found mutated and implicated in tumorigenesis. Most importantly, RUNX have now emerged as critical regulators of lymphocyte function against pathogenic infections and tumorigenic cells, the latter has now revolutionized our current understandings as to how RUNX proteins contribute to control tumor pathogenicity. These multifunctional roles of RUNX in mammalian immune responses and tissue homeostasis have led us to appreciate their value in controlling anti-tumor immune responses. Here, we summarize and discuss the role of RUNX in regulating the development and function of lymphocytes responding to foreign and tumorigenic threats and highlight their key roles in anti-tumor immunity.

27 October 2023 in Science Immunology
Verified
Journal Article
Closed access
STShiki Takamura
Shiki Takamura
ANAneela Nomura
Aneela Nomura
MKMasato Kubo
Masato Kubo
Sun et al. provide comprehensive evidence that the transcription factor BCL6 functions as a gatekeeper for CD8 + progenitor cell function in tumors and prevents their excessive terminal differentiation, thereby preserving this stem-like population for long-term tumor control.